Related Experiment Video
Updated: Jun 4, 2025
11:46
Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
Published on: April 27, 2014
17.7K
Exploring Drug Repurposing for Interstitial Cystitis/Bladder Pain Syndrome: Defining Novel Therapeutic Targets
Güldal Inal-Gültekin1, Zeliha Çetin2, Naşide Mangır3
1Department of Physiology, Faculty of Medicine, Istanbul Okan University, Istanbul, Türkiye.
Neurourology and Urodynamics
|December 26, 2024
Summary
Bioinformatics identified 21 potential drug repurposing candidates to reverse interstitial cystitis/bladder pain syndrome (IC/BPS) signatures. Further research is needed to validate these compounds for treating this chronic pain condition.
Area of Science:
- Bioinformatics and Computational Biology
- Genomics and Molecular Biology
- Pharmacology and Drug Discovery
Background:
- Interstitial cystitis/bladder pain syndrome (IC/BPS) is a severe, poorly understood chronic pain condition lacking effective therapies.
- Drug repurposing offers a viable strategy to accelerate the development of new treatments for IC/BPS by identifying novel uses for existing drugs.
- This study leverages bioinformatics to discover compounds capable of reversing the molecular disease signature of IC/BPS.
Purpose of the Study:
- To identify potential drug candidates for interstitial cystitis/bladder pain syndrome (IC/BPS) through bioinformatics analysis.
- To discover compounds that can reverse the specific gene expression patterns associated with IC/BPS.
- To accelerate the development of novel therapeutic strategies for IC/BPS.
Main Methods:
- Differential gene expression analysis was performed on IC/BPS patient datasets (GSE11783, GSE28242, GSE57560) comparing distinct phenotypes and controls.
- Bioinformatic platforms L1000CDS2 and cMAP were utilized to assess the reversal of the IC/BPS disease signature.
- Computational methods were employed to screen for and identify repurposable drug candidates.
Main Results:
- Twenty-one compounds were identified as potential candidates for drug repurposing.
- The identified compounds include small molecules, chemical compounds, natural products, and FDA-approved drugs.
- These repurposed drugs are currently indicated for conditions such as cancer, myelofibrosis, and diabetes.
Conclusions:
- Bioinformatics provides a powerful tool for identifying therapeutic agents for IC/BPS by analyzing large-scale molecular data.
- Prospective in vivo studies are essential to validate the efficacy of the identified repurposed drugs.
- Expanding genomic and clinical data resources for IC/BPS will enhance the success rate of drug repurposing efforts.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
01:26Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
01:21Drugs for Treatment of Constipation-Predominant IBS
133
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
133
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
208
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
208
01:29Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111
01:25Analgesia and Pain Management
496
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
496